Generic Victrelis Availability

Victrelis is a brand name of boceprevir, approved by the FDA in the following formulation(s):

VICTRELIS (boceprevir - capsule;oral)

Has a generic version of Victrelis been approved?

No. There is currently no therapeutically equivalent version of Victrelis available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Victrelis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Pharmaceutical formulations and methods of treatment using the same
    Patent 7,772,178
    Issued: August 10, 2010
    Inventor(s): Malcolm; Bruce A. & Bradley; Prudence K. & Pavlovsky; Anastasia & Cho; Wing-Kee Philip & Qiu; Zhihui
    Assignee(s): Schering Corporation
    Pharmaceutical formulations containing at least one compound of Formulae I-XXVI herein and at least one surfactant. Pharmaceutically acceptable carriers and excipients may also be included in the formulations. The formulations of the present invention are suited for use in single unit dosages.
    Patent expiration dates:
    • November 11, 2027
      ✓ 
      Patent use: TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE
      ✓ 
      Drug product
  • Administration of HCV protease inhibitors in combination with food to improve bioavailability
    Patent 8,119,602
    Issued: February 21, 2012
    Inventor(s): Zhang; Jenny & Gupta; Samir K.
    Assignee(s): Schering Corporation
    Methods of treating, preventing or ameliorating one or more symptoms of hepatitis C in a subject comprising the step of administering at least one HCV protease inhibitor in combination with food are provided. Also provided are methods of increasing bioavailability of an HCV protease inhibitor and methods of increasing serum levels of an HCV protease inhibitor in a subject. All methods comprise adminstering at least one HCV protease inhibitor in combination with food, the at least one HCV protease inhibitor selected from the group consisting of compounds of Formulae I-XXVI, described herein. Administration of compounds of the present invention in combination with food provides improved bioavailability and increased peak serum levels of the compounds as compared to administration without food.
    Patent expiration dates:
    • March 17, 2027
      ✓ 
      Patent use: TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH FOOD
  • Peptides as NS3-serine protease inhibitors of hepatitis C virus
    Patent RE43298
    Issued: April 3, 2012
    Inventor(s): Saksena; Anil K. & Girijavallabhan; Viyyoor Moopil & Lovey; Raymond G. & Jao; Edwin & Bennett; Frank & McCormick; Jinping L. & Wang; Haiyan & Pike; Russell E. & Bogen; Stephane L. & Chan; Tin-Yau & Liu; Yi-Tsung & Zhu; Zhaoning & Njoroge; F. George & Arasappan; Ashok & Parekh; Tejal
    Assignee(s): Schering Corporation Dendreon Corporation
    The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
    Patent expiration dates:
    • February 22, 2022
      ✓ 
      Patent use: TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • February 13, 2016 - NEW PATIENT POPULATION
    • February 27, 2016 - UPDATES TO THE CLINICAL STUDIES SECTION 14, OF THE PACKAGE INSERT (PI), WITH THE RESULTS OF CLINICAL TRIAL P06086
    • May 13, 2016 - NEW CHEMICAL ENTITY

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web4)